Paysign (PAYS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 7, 2025, at 4:00 P.M. PDT in Henderson, Nevada.
Shareholders will vote on director elections, executive compensation, advisory vote frequency, auditor ratification, and other business.
Record date for voting eligibility is March 10, 2025.
Voting matters and shareholder proposals
Election of seven director nominees to serve until the 2026 annual meeting.
Advisory vote on executive compensation for fiscal year 2025.
Advisory vote on the frequency of future executive compensation votes.
Ratification of Moss Adams LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Board recommends voting "FOR" all director nominees, executive compensation, auditor ratification, and a three-year frequency for say-on-pay votes.
Board of directors and corporate governance
Seven nominees are proposed for election to the board, each to serve a one-year term until the 2026 annual meeting.
Latest events from Paysign
- Rapid growth in patient affordability and tech-driven margin expansion offset plasma headwinds.PAYS
The MicroCap Rodeo Conference - NYC3 Feb 2026 - Strong revenue growth and market expansion in healthcare-focused prepaid payment solutions.PAYS
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 revenue up 30% year-over-year, net income positive, and 2024 guidance raised.PAYS
Q2 20242 Feb 2026 - Patient affordability business is rapidly scaling, driving strong growth and margin expansion.PAYS
Sidoti Micro-Cap Virtual Conference2 Feb 2026 - Q3 2024 revenue up 23%, pharma patient affordability revenue up 219% year-over-year.PAYS
Q3 202416 Jan 2026 - 2024 revenue up 23.5%, patient affordability soared 214.5%, 2025 outlook strong.PAYS
Q4 202425 Dec 2025 - Board recommends triennial say-on-pay, all directors up for election, and auditor ratification.PAYS
Proxy Filing1 Dec 2025 - Record Q2 revenue and profit, driven by pharma growth, margin expansion, and raised guidance.PAYS
Q2 202523 Nov 2025 - Proprietary tech, high retention, and innovation drive strong growth and positive analyst outlook.PAYS
17th Annual Southwest IDEAS Conference20 Nov 2025